Skip to content

US · KYNB · BIOTECHNOLOGY

Kyntra Bio, Inc. (KYNB) intrinsic value and stock valuation

$1.56as of 2026-11-21 · Mkt cap 29.43M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kyntra Bio, Inc. DCF and intrinsic value

InvestorsCraft values KYNB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KYNB’s statements →

Kyntra Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Francisco, CA 94133 kyntrabio.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$6.44M-48.4% 5y CAGRd
20122025
Net income
$183.5M
20122025
Free cash flow
-$-4.81M
20122025
Total equity
-$-17M
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$6.44M$29.6M$46.8M$140.7M$235.3M
Operating income-$-45.9M-$-150.42M-$-322.72M-$-301.02M-$-288.53M
Net income$183.5M-$-47.58M-$-284.23M-$-293.65M-$-290.02M
EPSd$45.4M-$-11.9M-$-73.07M-$-78.52M-$-78.6M
Operating cash flow-$-4.77M-$-138M-$-315.02M-$-145.93M-$-82.23M
Capital expenditure-$-40K-$-270K-$-2.52M-$-38.74M-$-30.19M
Free cash flow-$-4.81M-$-138.26M-$-317.54M-$-184.67M-$-112.42M
Total assets$119.6M$214.5M$423.5M$610.1M$773.8M
Total debt$85.5M$90.2M$170.5M$89.9M$99.7M
Net debt$37.7M$39.7M$56.8M-$-65.81M-$-71.5M
Total equity-$-17M-$-183.63M-$-162.2M-$-1.48M$229.1M
Cash and short-term investments$89M$50.5M$235.6M$422M$405.2M
Income statement
20252024202320222021
Revenue$6.44M$29.6M$46.8M$140.7M$235.3M
Cost of revenue$560K$15.6M$3.96M$20.3M$449.2M
Gross profit$5.88M$14.1M$42.8M$120.5M-$-213.88M
Research and development expenses$23.5M$95.7M$266.5M$296.8M$387M
Selling, general and administrative expenses$27.7M$49.3M$86.5M$124.7M$0.00
Other expenses$550K$19.5M$12.6M$0.00-$-312.4M
Operating expenses$51.8M$164.5M$365.6M$421.5M$74.7M
Cost and expenses$52.3M$180M$369.5M$441.8M$523.8M
Interest income$2.94M$5.3M$7.59M$7.6M—
Interest expense$8.76M$8.25M$8.1M$1.44M$1.07M
Depreciation and amortization$750K$2.69M$9.93M$10.6M$14.8M
Ebitda-$-57.55M-$-142.43M-$-305.2M-$-282.82M-$-333.72M
Operating income-$-45.9M-$-150.42M-$-322.72M-$-301.02M-$-288.53M
Total other income/expenses, net-$-12.4M-$-2.95M-$-500K$7.73M-$-1.15M
Income before tax-$-58.29M-$-153.37M-$-323.22M-$-293.3M-$-289.68M
Income tax expense-$-90K-$-270K-$-250K$360K$350K
Net income$183.5M-$-47.58M-$-284.23M-$-293.65M-$-290.02M
Weighted average shares outstanding$4.04M$4M$3.89M$3.74M$3.69M
Weighted average diluted shares outstanding$4.04M$4M$3.89M$3.74M$3.69M
Balance sheet
20252024202320222021
Cash and short-term investments$89M$50.5M$235.6M$422M$405.2M
Net receivables$4.22M$480K$41.1M$16.3M$25.4M
Inventory$3.74M$3.15M$41.6M$40.4M$31M
Total current assets$99.1M$196.5M$331.6M$492.8M$474.1M
Property, plant and equipment, net$0.00$100K$81.4M$100.5M$119.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$20.2M$0.00$5.29M$9.41M$171.6M
Total non-current assets$20.5M$18M$92M$117.3M$299.8M
Total assets$119.6M$214.5M$423.5M$610.1M$773.8M
Accounts payable$3.75M$5.06M$18M$30.8M$26.1M
Short-term debt$0.00$30K$14.1M$10.3M$10.9M
Deferred revenue$5.31M$27.3M$12.7M$12.7M$19M
Total current liabilities$29.2M$133.3M$217.7M$273.6M$225.5M
Long-term debt$85.5M$90.2M$156.3M$79.6M$88.8M
Deferred revenue, non-current$260K$114.7M$157.6M$185.7M$186.8M
Total non-current liabilities$85.9M$264.9M$368.1M$338M$319.2M
Capital lease obligations$0.00$70K$80.7M$89.9M$99.7M
Total liabilities$115.1M$398.2M$585.7M$611.6M$544.7M
Common stock$1.01M$1.01M$990K$940K$930K
Retained earnings-$-1.71B-$-1.89B-$-1.84B-$-1.56B-$-1.26B
Accumulated other comprehensive income (loss)-$-2.18M-$-5.73M-$-6.88M-$-5.72M-$-4.16M
Total equity-$-17M-$-183.63M-$-162.2M-$-1.48M$229.1M
Total investments$61.3M$0.00$127.2M$275.7M$405.6M
Total debt$85.5M$90.2M$170.5M$89.9M$99.7M
Net debt$37.7M$39.7M$56.8M-$-65.81M-$-71.5M
Cash flow statement
20252024202320222021
Net income$183.5M-$-47.58M-$-284.23M-$-293.65M-$-290.02M
Depreciation and amortization$750K$2.69M$9.93M$10.6M$14.8M
Stock-based compensation$6.58M$25.2M$50.8M$65.6M$71.2M
Change in working capital-$-153.03M-$-117.46M-$-119.69M$70.4M$60.1M
Accounts receivable-$-2.54M-$-6.74M$3.43M$770K$25.2M
Inventory$5.36M$22.3M-$-1.7M-$-11M-$-14.16M
Accounts payable-$-27.65M$14.5M-$-15.51M$5.91M$810K
Net cash provided by operating activities-$-4.77M-$-138M-$-315.02M-$-145.93M-$-82.23M
Investments in property, plant and equipment-$-40K-$-270K-$-2.52M-$-3.74M-$-5.19M
Acquisitions, net$0.00$1.05M$660K$0.00$0.00
Net cash used for investing activities$35.4M$126M$153.7M$89.1M-$-426.97M
Common stock issued$0.00$140K$48.4M$4.18M$12.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-2.23M$0.00$0.00$0.00
Net cash used for financing activities-$-86.03M-$-260K$122.8M$46.8M-$-560K
Net change in cash-$-54.31M-$-11.51M-$-42.01M-$-15.52M-$-507.17M
Cash at end of period$47.9M$102.2M$113.7M$155.7M$171.2M
Operating cash flow-$-4.77M-$-138M-$-315.02M-$-145.93M-$-82.23M
Capital expenditure-$-40K-$-270K-$-2.52M-$-38.74M-$-30.19M
Free cash flow-$-4.81M-$-138.26M-$-317.54M-$-184.67M-$-112.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kyntra Bio, Inc.

        Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

        CEO
        Thane Wettig
        Employees
        34
        Beta
        0.97

        Explore

        Frequently asked questions

        What is the intrinsic value of Kyntra Bio, Inc. (KYNB)?

        InvestorsCraft does not currently publish an intrinsic value for KYNB. How the IC value is calculated.

        Is KYNB undervalued?

        InvestorsCraft does not publish an undervaluation signal for KYNB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.